Christopher Ellis Archives
Oct. 22, 2020—A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.
Sep. 17, 2020—Vanderbilt Heart and Vascular Institute (VHVI) has implanted its first V-Wave, an interatrial shunt device, as a part of a multi-center clinical trial.
Mar. 12, 2020—In February, Martha Hawks became the Southeast’s first recipient of the Medtronic Micra AV, the latest version of the tiny pacemaker that Vanderbilt Heart and Vascular Institute began testing in a clinical trial in 2014. The FDA approved the latest device in January.
Feb. 9, 2017—Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
Aug. 25, 2016—Peggy Tubb doesn’t recall her exact reaction when she was told she could stop taking blood thinners to treat atrial fibrillation (AF), but the news changed her life.
Jun. 17, 2015—Vanderbilt Heart and Vascular Institute now offers patients with atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke, potentially avoiding the long-term use of blood thinners such as warfarin.
Aug. 8, 2013—Vanderbilt Heart and Vascular Institute is the first in the United States to use a new fully resorbable “envelope” that encloses implantable cardiac devices, such as pacemakers and internal cardioverter defibrillators (ICDs), and helps prevent surgical site infections.
Aug. 1, 2013—People with the most common irregular heart rhythm known as atrial fibrillation (AF) are at greater risk for stroke due to the formation of clots in the left atrial appendage (LAA), a small pouch which empties blood into the left atrium.
Apr. 11, 2013—The state of Michael Stanbery’s health was shocking.
May. 27, 2011—A new implantable device currently being studied gives heart failure patients the ability to monitor their heart and take action when their condition begins to worsen.